Delcath Systems

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DCTH and other ETFs, options, and stocks.

About DCTH

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. 

CEO
Gerard J. Michel
CEOGerard J. Michel
Employees
96
Employees96
Headquarters
Queensbury, New York
HeadquartersQueensbury, New York
Founded
1988
Founded1988
Employees
96
Employees96

DCTH Key Statistics

Market cap
365.14M
Market cap365.14M
Price-Earnings ratio
1.22K
Price-Earnings ratio1.22K
Dividend yield
Dividend yield
Average volume
416.14K
Average volume416.14K
High today
$10.56
High today$10.56
Low today
$9.97
Low today$9.97
Open price
$10.32
Open price$10.32
Volume
50.04K
Volume50.04K
52 Week high
$18.23
52 Week high$18.23
52 Week low
$8.12
52 Week low$8.12

Stock Snapshot

Delcath Systems(DCTH) stock is priced at $10.34, giving the company a market capitalization of 365.14M. It carries a P/E multiple of 1224.42.

On 2026-01-09, Delcath Systems(DCTH) stock traded between a low of $9.97 and a high of $10.56. Shares are currently priced at $10.34, which is +3.7% above the low and -2.1% below the high.

Delcath Systems(DCTH) shares are trading with a volume of 50.04K, against a daily average of 416.14K.

In the last year, Delcath Systems(DCTH) shares hit a 52-week high of $18.23 and a 52-week low of $8.12.

In the last year, Delcath Systems(DCTH) shares hit a 52-week high of $18.23 and a 52-week low of $8.12.

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own DCTH. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.